Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has issued an announcement.
PharmaTher Holdings Ltd. announced that it is on track to resubmit information to the FDA by the end of February 2025, following a complete response letter that identified minor deficiencies. The company anticipates that this minor amendment will lead to a new FDA approval date in the second quarter of 2025 for ketamine, which is essential for anesthesia and pain relief, and is also used for mental health and neurological disorders. The successful approval could significantly strengthen PharmaTher’s market position as a key innovator in ketamine-based treatments, potentially impacting millions of patients worldwide.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to address global unmet medical needs in anesthesia, sedation, pain, mental health, neurological, and medical countermeasures indications.
YTD Price Performance: -3.33%
Average Trading Volume: 235,703
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.39M
For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.
